← Leaderboards
Sheila Connelly
Advanced Vision Therapies, Inc.
$3,558,642
Attributed
$3,558,642
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2005–06$2M$1.5M$1M$500K$0
'05
'06
Funding mix
By agency
NIH$3,558,642 · 5
By mechanism
R44$2,383,335 · 1
R43$1,175,307 · 4
Top collaborators
No co-investigators on record.
Most similar at Advanced Vision Therapies, Inc.
Same institution · by research overlap
- Tianci Luo$791,348
Others in their field
Top investigators on “Transfection /Expression Vector”
- William W Hauswirth · University Of Florida$14,472,513
- Kenneth G Cornetta · Indiana Univ-Purdue Univ At Indianapolis$10,466,261
- Klaus H. Kaestner · University Of Pennsylvania$8,467,407
- David T Curiel · University Of Alabama At Birmingham$8,321,535
- Timothy A Cross · Florida State University$7,979,166
- John H Wolfe · Children'S Hospital Of Philadelphia$7,103,743
Research focus
Transfection /Expression VectorLaboratory MouseMacular DegenerationLentivirusGene TherapyGene ExpressionGene Delivery SystemBiotechnologyAngiogenesis InhibitorsGreen Fluorescent ProteinsReporter GenesTechnology /Technique DevelopmentTherapy Design /DevelopmentTissue /Cell CultureHela CellsHuman TissueEnzyme Linked Immunosorbent AssayEdemaMacaca FascicularisDisease /Disorder ModelNonhuman Therapy EvaluationOrgan CulturePlasmidsTranscription Factor
Grant awards (7)
Novel Therapy for Wet Age-Related Macular Degeneration$1,095,601
R44 · FY2006 · EY · contact PI
Novel Strategy for BIV Vector Site-Specific Integration$349,780
R43 · FY2006 · GM · contact PI
Novel Therapy for Wet Age-Related Macular Degeneration$1,064,532
R44 · FY2005 · EY
Evaluation of Kininostatin for Treatment of Wet AMD$149,800
R43 · FY2005 · EY
Evaluation of novel BIV-based vectors in vivo$541,836
R43 · FY2004 · EY
Novel Therapy for Wet Age-Related Macular Degeneration$223,202
R44 · FY2004 · EY
Novel Lentiviral Vector with Regulatable Gene Expression$133,891
R43 · FY2004 · EY